Injectable insulin-lysozyme-loaded nanogels with enzymatically-controlled degradation and release for basal insulin treatment: In vitro characterization and in vivo observation.
暂无分享,去创建一个
Magnus Röding | Magnus Nydén | Dean-Mo Liu | Meng-Hsuan Hsiao | M. Röding | M. Nydén | Meng-Hsuan Hsiao | Mikael Larsson | Mikael Larsson | Hao-Syun Chou | Yi-Chieh Chen | Hao-Syun Chou | Dean‐Mo Liu | Yi-Chieh Chen
[1] Y. Chen,et al. Design and characterization of a novel amphiphilic chitosan nanocapsule-based thermo-gelling biogel with sustained in vivo release of the hydrophilic anti-epilepsy drug ethosuximide. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[2] Kai Zhang,et al. Modulated insulin permeation across a glucose-sensitive polymeric composite membrane. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[3] D. White,et al. Diabetic rats and mice are resistant to porcine and human insulin: flawed experimental models for testing islet xenografts , 2009, Xenotransplantation.
[4] A. Larsson,et al. Evaluation of Carboxymethyl-Hexanoyl Chitosan as a Protein Nanocarrier , 2013 .
[5] Thomas Kazen. Purification , 2004, Nature Biotechnology.
[6] S. Neau,et al. In vitro degradation of chitosan by bacterial enzymes from rat cecal and colonic contents. , 2002, Biomaterials.
[7] V. Gudnason,et al. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .
[8] Hui-Yi Lin,et al. A pH-responsive amphiphilic chitosan-pyranine core-shell nanoparticle for controlled drug delivery, imaging and intracellular pH measurement. , 2014, Journal of materials chemistry. B.
[9] S. Chiou,et al. A temperature-induced and shear-reversible assembly of latanoprost-loaded amphiphilic chitosan colloids: characterization and in vivo glaucoma treatment. , 2014, Acta biomaterialia.
[10] C. P. Sharma,et al. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. , 1997, Journal of biomedical materials research.
[11] N. C. Price,et al. The use of circular dichroism in the investigation of protein structure and function. , 2000, Current protein & peptide science.
[12] Richard Barnett,et al. Diabetes mellitus. , 1993, The Medical journal of Australia.
[13] M. Feinglos,et al. Basal insulin therapy in type 2 diabetes. , 2005, The Journal of the American Board of Family Practice.
[14] San-Yuan Chen,et al. Self-assembly behavior and doxorubicin-loading capacity of acylated carboxymethyl chitosans. , 2009, The journal of physical chemistry. B.
[15] S. Withers,et al. Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate , 2001, Nature.
[16] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[17] B. Sarmento,et al. Oral Insulin Delivery: How Far are We? , 2013, Journal of diabetes science and technology.
[18] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[19] R. Langer,et al. Enzymatically controlled drug delivery. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[20] Shih-bin Lin,et al. Low molecular weight chitosan prepared with the aid of cellulase, lysozyme and chitinase: Characterisation and antibacterial activity , 2009 .
[21] J. Danesh,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.
[22] J. Hankiewicz,et al. Lysozyme in human body fluids. , 1974, Clinica chimica acta; international journal of clinical chemistry.
[23] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[24] Tao Gong,et al. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. , 2012, Biomaterials.
[25] B. Preston,et al. Purification, characterization, and biosynthesis of bovine cartilage lysozyme isoforms. , 1997, Archives of biochemistry and biophysics.
[26] Y. Kuo,et al. Caffeic Acid Phenylethyl Amide Protects against the Metabolic Consequences in Diabetes Mellitus Induced by Diet and Streptozocin , 2012, Evidence-based complementary and alternative medicine : eCAM.
[27] S. Yaturu. Insulin therapies: Current and future trends at dawn. , 2013, World journal of diabetes.
[28] G. Park,et al. Long-acting insulin analogs. , 1999, Diabetes care.
[29] L. Heinemann,et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. , 2004, Diabetes.
[30] R. Henkin. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action. , 2010, Nutrition.
[31] A. Surolia,et al. Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus , 2010, Proceedings of the National Academy of Sciences.
[32] Daniel G Anderson,et al. Injectable nano-network for glucose-mediated insulin delivery. , 2013, ACS nano.
[33] San-Yuan Chen,et al. Self-Assembled Hollow Nanocapsule from Amphiphatic Carboxymethyl-hexanoyl Chitosan as Drug Carrier , 2008 .
[34] Xiaojun Ma,et al. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. , 2005, Carbohydrate research.
[35] S. Neau,et al. In vitro degradation of chitosan by a commercial enzyme preparation: effect of molecular weight and degree of deacetylation. , 2001, Biomaterials.